CHARM hsCRP Methodology

Your Rapid Indicator for Cardiovascular Inflammation

High-sensitivity C-reactive protein (hsCRP) is a powerful biomarker for detecting systemic inflammation — a key driver of atherosclerotic cardiovascular disease (ASCVD). An hsCRP level of ≥ 2 mg/L signals elevated cardiovascular risk, even in patients with optimised LDL-cholesterol levels. With CHARM cm, you can measure hsCRP in minutes at the point of care, giving you the insights you need to make timely, informed clinical decisions^1-3.

Why hsCRP Testing Matters

Systemic inflammation contributes to:

• Plaque formation and rupture leading to acute myocardial infarction (AMI)
• Larger infarct sizes and higher recurrence risk post-MI
• Faster progression and decompensation in heart failure

Clinical studies show:

• hsCRP is a stronger predictor of cardiovascular death than LDL-C in statin-treated patients
• Lowering hsCRP below 2 mg/L can reduce major adverse cardiovascular events by 25% and all-cause mortality by 31%
  
  

Contact a CHARM Specialist

hsCRP + Lp(a) = A Complete Risk Profile

While Lp(a) reflects genetic cardiovascular risk, hsCRP reveals active inflammatory risk.
Together, these two markers give a more complete picture - enabling precision prevention and treatment strategies.
With CHARM cm’s compact, reliable system, both tests can be seamlessly integrated into your cardiovascular risk assessment workflow.

Evidence-Based Confidence

Leading guidelines support hsCRP testing:

• American College of Cardiology/American Heart Association (ACC/AHA):
  hsCRP ≥ 2 mg/L is a risk-enhancing factor for ASCVD; testing is recommended in both primary and secondary prevention
• European Society of Cardiology (ESC):
  hsCRP should be considered in the diagnostic work-up of suspected chronic coronary syndrome (CCS)

How It Works

• Collect a small blood sample at the point of care
• Run the hsCRP test on the CHARM cm analyser
• Read precise results in minutes — during the patient consultation
• Act immediately with personalised treatment decisions

Elevate Your Cardiovascular Care

Adding hsCRP testing to your CHARM cm platform empowers you to:

• Detect hidden residual risk in statin-treated patients
• Monitor inflammation response to targeted therapies
• Improve patient outcomes through early intervention

References

1. Lawler PR et al. Eur Heart J 2021;42:113–131
2. Hansson GK. N Engl J Med 2005;352:1685–1695;
3. Ridker PM. J Am Coll Cardiol 2018;72:3320